# NPI-002 Intravitreal Implant for the Delay of Cataract Progression

> **NCT05026632** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nacuity Pharmaceuticals, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** NPI-002 Intravitreal Implant

## Key facts

- **NCT ID:** NCT05026632
- **Lead sponsor:** Nacuity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-27
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05026632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05026632, "NPI-002 Intravitreal Implant for the Delay of Cataract Progression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05026632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*